There is low insulin availability in the Philippines and investigators recommend policy and regulatory reviews.
Investigators reporting on insulin availability in the Philippines said affordability and access are inadequate for many in the Southeast Asia country and recommended measures for improvement, including:
Authors of the study, presented at 2021 ISPOR Virtual, said “insulins were affordable in the public sector, but access was affected by low availability.” Private-sector patients faced higher costs compounded by limited competition. Policy and regulatory reviews to improve insulin availability would help, investigators said.
Insulin pricing, availability, and affordability were reviewed in 6 regions of the Philippines following the imposition of a January 2019 value-added tax exemption policy. Insulin prices were compared with international reference prices (IRPs) and affordability was based on the number of days’ wages needed for the “lowest-paid unskilled government worker” to purchase a monthly supply of insulin (10 mL, 100 IU/mL).
The public sector was defined as public hospitals and medicine outlets; and the private sector, private hospitals and retail pharmacies. Mean availability of insulin originator products and biosimilars was 2.8% and 50.0%, respectively, in the public sector and 63.9% and 61.1% in the private sector.
LPG metaformin was the only insulin that met the World Health Organization target of 80% availability in both sectors, and originator versions of most insulins and biosimilars, along with analogue insulins, were not available in the public sector, except for human short-acting and analogue long-acting insulins (2.8% availability in both cases).
Sources of Insulin
All insulin products included in the study were imported, and 3 companies (Eli Lilly, Sanofi-Aventis, Novo Nordisk) accounted for 65% of those products, authors wrote. Vials were the most common form of insulin available (55%), followed by prefilled pens (41.7%) and cartridges (3.2%). Vials were in general cheaper than pens and cartridges, and biosimilars were cheaper than originator products, according to findings.
Insulin in the private sector was 1.05 to 3.66 times more costly than IRPs; in the public sector, prices were uniformly less costly than the IRP. “Purchasing 10 mL of human and analogue insulin in the private sector would need 2 to 4 days’ and 4 to 8 days’ wages, respectively,” the authors wrote.
Although affordability was based on wages of the lowest-paid government workers, the authors noted that “a significant portion of the population earns less than the lowest-paid government worker.”
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.